Access count of this item: 59

Files in This Item:
File Description SizeFormat 
s12885-015-1041-3.pdf2.07 MBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSuzuki, Eijija
dc.contributor.authorKataoka, Tatsuki R.ja
dc.contributor.authorHirata, Masahiroja
dc.contributor.authorKawaguchi, Kosukeja
dc.contributor.authorNishie, Marikoja
dc.contributor.authorHaga, Hironorija
dc.contributor.authorToi, Masakazuja
dc.contributor.alternative片岡, 竜貴ja
dc.contributor.alternative羽賀, 博典ja
dc.contributor.alternative戸井, 雅和ja
dc.date.accessioned2016-05-26T05:36:20Z-
dc.date.available2016-05-26T05:36:20Z-
dc.date.issued2015-02-06ja
dc.identifier.issn1471-2407ja
dc.identifier.urihttp://hdl.handle.net/2433/213940-
dc.description.abstractBackground: Trogocytosis is defined as the transfer of cell-surface membrane proteins and membrane patches from one cell to another through contact. It is reported that human epidermal growth factor receptor 2 (HER2) could be transferred from cancer cells to monocytes via trogocytosis; however, the clinical significance of this is unknown. The aim of this study is to demonstrate the presence and evaluate the clinical significance of HER2+ tumor-infiltrated immune cells (arising through HER2 trogocytosis) in HER2-overexpressing (HER2+) breast cancer patients receiving trastuzumab-based primary systemic therapy (PST). Methods: To assess the trogocytosis of HER2 from cancer cells to immune cells, and to evaluate the up- and down-regulation of HER2 on immune and cancer cells, peripheral blood mononuclear cells from healthy volunteers and breast cancer patients were co-cultured with HER2+ and HER2-negative breast cancer cell lines with and without trastuzumab, respectively. The correlation between HER2 expression on tumor-infiltrated immune cells and a pathological complete response (pCR) in HER2+ breast cancer patients treated with trastuzumab-based PST was analyzed. Results: HER2 was transferred from HER2+ breast cancer cells to monocytes and natural killer cells by trogocytosis. Trastuzumab-mediated trogocytosed-HER2+ effector cells exhibited greater CD107a expression than non-HER2-trogocytosed effector cells. In breast cancer patients, HER2 expression on tumor-infiltrated immune cells in treatment naïve HER2+ tumors was associated with a pCR to trastuzumab-based PST. Conclusions: HER2-trogocytosis is visible evidence of tumor microenvironment interaction between cancer cells and immune cells. Given that effective contact between these cells is critical for immune destruction of target cancer cells, this interaction is of great significance. It is possible that HER2 trogocytosis could be used as a predictive biomarker for trastuzumab-based PST efficacy in HER2+ breast cancer patients.ja
dc.format.mimetypeapplication/pdfja
dc.language.isoengja
dc.publisherBioMed Central Ltd.ja
dc.rights© Suzuki et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.ja
dc.subjectBreast cancerja
dc.subjectHER2/ Trogocytosisja
dc.subjectTrastuzumabja
dc.titleTrogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patientsja
dc.type.niitypeJournal Articleja
dc.identifier.jtitleBMC Cancerja
dc.identifier.volume15ja
dc.relation.doi10.1186/s12885-015-1041-3ja
dc.textversionpublisherja
dc.identifier.artnum39ja
Appears in Collections:Journal Articles

Show simple item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.